Medexus Pharmaceuticals Inc. announced to highlight positive new data on treosulfan that researchers at Toronto's Princess Margaret Hospital (PMH) recently presented at MDS 2023, the 17th annual International Congress on Myelodysplastic Syndromes, held in Marseille, France. The study, a retrospective analysis of patient outcomes, further confirms Medexus's optimism regarding treosulfan's potential positive impact in both Canada and the United States. The MDS 2023 presentation is substantially consistent with the previously published final study results and analysis of the pivotal phase 3 clinical trial of treosulfan, which Medexus announced in June 2022.

Among other things, that earlier study demonstrated clinically relevant superiority of treosulfan over a reduced-intensity conditioning busulfan regimen with regard to event-free survival, that study's primary endpoint. Treosulfan is part of a preparative regimen for allogeneic hematopoietic stem cell transplantation, to be used in combination with fludarabine, used in treating eligible patients with acute myeloid leukemia and myelodysplastic syndromes. Final study results and analysis of The pivotal phase 3 clinical trial of Treosulfan conducted by medac GmbH, which was published in the American Journal of Hematology, concluded that the study demonstrates clinically relevant superiority of treos sulfan over a widely applied "reduced-intensity conditioning" busulfan regimen with regard To its primary endpoint, event-free survival.

The publication also includes favorable conclusions on two key secondary endpoints, finding that overall survival with treosulfan was superior compared to busulfan and that non-relapse mortality for patients in the treosulfan arm was lower than for patients in the busulfan arm. During the phase 3 clinical trial of treOSulfan, treatment emergent adverse events (TEAEs) were reported by 92.6% of patients in the treosulf an treatment group.